

Privately Funded Seminar Disclosure Report

Seminar host: George Mason University Law & Economics Center
Seminar title: Pharmaceutical Symposium at Antonin Scalia Law School (April 2019)
Location: Arlington, VA
Seminar dates: 04/14/19 to 04/16/19

Judge name: Gene Davis

Disclosed by provider as of start of seminar

Topic	Speaker
Introduction and Overview	Gregory Conko (Law and Economics Center)
Lecture 1: The Economics of Drug Development	Kenneth Kaitin (Director: Tufts University)
Lecture 2: The Hatch-Waxman Act and Generic Drugs	Erika Lietzan (University of Missouri School of Law)
Lecture 3: The Regulation of Labeling, Advertizing, and Promotion	Ralph Hall (University of Minnesota Law School)
Luncheon Keynote Address: The Evolving Standards for Expert Evidence	David Bernstein (Antonin Scalia Law School)
Luncheon Keynote Address: The Evolving Standards for Expert Evidence	David Faigman (University of California Hastings College of Law)
Luncheon Keynote Address: The Evolving Standards for Expert Evidence	Michael Imbroscio (Covington & Burling LLP)
Luncheon Keynote Address: The Evolving Standards for Expert Evidence	Jason Lichtman (Leiff Cabraser Heimann & Bernstein LLP)
Luncheon Keynote Address: The Evolving Standards for Expert Evidence	David Wecht (Supreme Court of Pennsylvania)
Luncheon Keynote Address: The Social Value of Health Tech Innovation	Thomas Philipson (White House Council of Economic Advisors)
Opening Address: The Changing Face of Pharmaceutical Litigation	Daniel Troy (Former General Counsel: GlaxoSmithKline)
Opening Address: The Changing Face of Pharmaceutical Litigation	George Jespen (Partner: Shipman & Goodwin LLP)
Panel I: Development, Pricing, and the Market for Pharmaceuticals	James Capretta (American Enterprise Institute)
Panel I: Development, Pricing, and the Market for Pharmaceuticals	Merrill Goozner (Modern Healthcare)
Panel I: Development, Pricing, and the Market for Pharmaceuticals	Charles Silver (University of Texas School of Law)
Panel I: Development, Pricing, and the Market for Pharmaceuticals	Aaron Vandervelde (Berkeley Research Group)
Panel II: Antitrust Issues and Brand-Generic Disputes	Sumanth Addanki (NERA Economic Consulting)
Panel II: Antitrust Issues and Brand-Generic Disputes	David Balto (Law Offices of David Balto)
Panel II: Antitrust Issues and Brand-Generic Disputes	Markus Meier (Federal Trade Commission Bureau of Competition)
Panel II: Antitrust Issues and Brand-Generic Disputes	Christopher Holman (University of Missouri-Kansas City School of Law)
Panel II: Antitrust Issues and Brand-Generic Disputes	John Yun (Antonin Scalia Law School)
Panel III: Who Really Pays for Drugs and How Much?	Anupam Jena (Harvard Medical School)

Privately Funded Seminar Disclosure Report

Panel III: Who Really Pays for Drugs and How Much?	Richard Manning (Partner: Bates White)
Panel III: Who Really Pays for Drugs and How Much?	David Hyman (Georgetown University Law Center)
Panel IV: Advertising, Promotion, and the False Claims Act	Kalah Auchincloss (Greenleaf Health)
Panel IV: Advertising, Promotion, and the False Claims Act	James Beck (Reed Smith LLP)
Panel IV: Advertising, Promotion, and the False Claims Act	Robert Booth II (Colorado Medicaid Fraud Control Unit)
Panel IV: Advertising, Promotion, and the False Claims Act	Wayne Pines (APCO Worldwide)
Panel IV: Advertising, Promotion, and the False Claims Act	Gregory Conko (Law and Economics Center)
Panel V: Labeling, Preemption, and Products Liability	Andrew Bayman (King & Spaulding LLP)
Panel V: Labeling, Preemption, and Products Liability	Max Kennerly (Kennerly Loutey LLP)
Panel V: Labeling, Preemption, and Products Liability	Jeremy Newman (Hanson, Todd, Figel & Frederick PLLC)
Panel V: Labeling, Preemption, and Products Liability	Rebecca Wood (Sidley Austin LLP)
Panel V: Labeling, Preemption, and Products Liability	Michael Krauss (Antonin Scalia Law School)
Welcoming Remarks	Henry Butler (Antonin Scalia Law School)

Funder

George Mason University Foundation